Ph.D., CEO, ProterixBio, Inc
Michael Miller is currently CEO of ProterixBio, a company developing novel molecular assessments to transform the care of patients with chronic respiratory disease. He has over 20 years of experience developing and launching products in the life science and high technology industries. Prior to ProterixBio, he held the position of VP of Product Development and Operations as BioScale which commercialized an automated immunoassay platform utilizing a unique non-optical detection method based on MEMS technology. Previous positions included product development positions at Axsun Technologies, a company producing optical subsystems for telecommunications and medical device markets, and Physical Sciences Inc., where he worked on instrumentation and control devices for aerospace applications. Michael earned a B.S. in Mechanical Engineering from the Rensselaer Polytechnic Institute, and an M.S. and Ph.D. in Mechanical Engineering from Stanford University. He is inventor or co-inventor on over 25 issued patents with multiple additional pending patent applications.
Clinical Dx Showcase: ProterixBio
ProterixBio is developing molecular assessments to transform the care of patients with chronic respiratory disease, initially focusing on COPD. Blood-based biomarker combinations have the potential to accelerate therapeutics development and improve clinical outcomes.
Molecular Assessments for Chronic Respiratory Disease